Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers : A case report
Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70-year-old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Clinical case reports - 6(2018), 7 vom: 29. Juli, Seite 1338-1341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshimura, Akihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 26.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ccr3.1627 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286312646 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286312646 | ||
| 003 | DE-627 | ||
| 005 | 20231225051422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccr3.1627 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0954.xml |
| 035 | |a (DE-627)NLM286312646 | ||
| 035 | |a (NLM)29988633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshimura, Akihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers |b A case report |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70-year-old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a pseudoprogression | |
| 650 | 4 | |a pulmonary pleomorphic carcinoma | |
| 650 | 4 | |a tumor marker | |
| 700 | 1 | |a Takumi, Chieko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hamashima, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yuba, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Urata, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Noriya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical case reports |d 2013 |g 6(2018), 7 vom: 29. Juli, Seite 1338-1341 |w (DE-627)NLM234405864 |x 2050-0904 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2018 |g number:7 |g day:29 |g month:07 |g pages:1338-1341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccr3.1627 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2018 |e 7 |b 29 |c 07 |h 1338-1341 | ||